Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Operating Leases (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Operating Leases for 6 consecutive years, with $30.7 million as the latest value for Q2 2025.

  • On a quarterly basis, Operating Leases fell 33.01% to $30.7 million in Q2 2025 year-over-year; TTM through Jun 2025 was $30.7 million, a 33.01% decrease, with the full-year FY2024 number at $42.8 million, down 11.81% from a year prior.
  • Operating Leases was $30.7 million for Q2 2025 at Relay Therapeutics, down from $41.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $53.5 million in Q4 2022 to a low of $20.0 million in Q2 2022.
  • A 5-year average of $37.3 million and a median of $42.8 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 155.25% in 2023, then plummeted 33.01% in 2025.
  • Relay Therapeutics' Operating Leases stood at $21.1 million in 2021, then skyrocketed by 153.92% to $53.5 million in 2022, then fell by 9.28% to $48.5 million in 2023, then fell by 11.81% to $42.8 million in 2024, then fell by 28.33% to $30.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Operating Leases are $30.7 million (Q2 2025), $41.2 million (Q1 2025), and $42.8 million (Q4 2024).